上海第一医药股份有限公司2025年年度业绩预告

Group 1 - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 41.5 million and 62 million yuan, representing a decrease of 10.10613 million to 12.15613 million yuan compared to the previous year, which is a year-on-year decrease of 61.98% to 74.55% [2][6] - The company anticipates a net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, to be between 4.9 million and 7.3 million yuan, with a potential decrease of 197.4 thousand yuan to an increase of 42.6 thousand yuan compared to the previous year, reflecting a year-on-year change of -28.72% to +6.20% [2][6] - The decrease in net profit is primarily attributed to the absence of compensation income from property expropriation that was present in the previous year [10] Group 2 - The company plans to use idle self-owned funds for entrusted wealth management, with a total amount not exceeding 300 million yuan, to improve the efficiency of fund utilization while ensuring normal operational liquidity [17][30] - The investment will focus on fixed-income products with a risk level of R2 or below, and the entrusted wealth management will be conducted with financial institutions that do not have a related party relationship with the company [19][30] - The board of directors has approved the wealth management plan, which will be effective until December 31, 2026, allowing for rolling use of the fund amount within the specified limit [20][30]